• PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP). (wikipedia.org)
  • PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment. (wikipedia.org)
  • In addition to their use in cancer therapy, PARP inhibitors are considered a potential treatment for acute life-threatening diseases, such as stroke and myocardial infarction, as well as for long-term neurodegenerative diseases. (wikipedia.org)
  • Combining radiation therapy with PARP inhibitors offers promise, since the inhibitors would lead to formation of double strand breaks from the single-strand breaks generated by the radiotherapy in tumor tissue with BRCA1/BRCA2 mutations. (wikipedia.org)
  • PARP inhibitors lead to trapping of PARP proteins on DNA in addition to blocking their catalytic action. (wikipedia.org)
  • Some cancer cells that lack the tumor suppressor PTEN may be sensitive to PARP inhibitors because of downregulation of Rad51, a critical homologous recombination component, although other data suggest PTEN may not regulate Rad51. (wikipedia.org)
  • Hence PARP inhibitors may be effective against many PTEN-defective tumours (e.g. some aggressive prostate cancers). (wikipedia.org)
  • Cancer cells that are low in oxygen (e.g. in fast growing tumors) are sensitive to PARP inhibitors. (wikipedia.org)
  • PARP inhibitors such as olaparib, under experimental conditions, appear to be beneficial in limiting atrial fibrillation and other DNA damage associated cardiovascular diseases. (wikipedia.org)
  • Here, we investigated a radioiodinated PARP inhibitor, [ 125 I]KX1, and show drug target specific DNA damage and subsequent killing of BRCA1 and non-BRCA mutant ovarian cancer cells at sub-pharmacological concentrations several orders of magnitude lower than traditional PARP inhibitors. (osti.gov)
  • PARP inhibitors can destroy cancer cells that are not good at repairing DNA damage. (cancersa.org.au)
  • In addition, the authors showed that blocking PARP activity with the competitive PARP inhibitors. (the-scientist.com)
  • Major companies are poised to profit from Cougar Biotechnology's albiraterone, a promising therapy for hormone-refractory prostate cancer, Medarex's ipilimumab, a potential blockbuster in hard-to-treat malignant melanoma, and PARP inhibitors by BiPar and KuDOS Pharmaceuticals. (pharmexec.com)
  • Harrision D, Gravells P, Thompson R & Bryant HE (2020) Poly(ADP-Ribose) glycohydrolase (PARG) vs. poly(ADP-Ribose) polymerase (PARP) - function in genome maintenance and relevance of inhibitors for anti-cancer therapy . (sheffield.ac.uk)
  • As part of our coverage of the 2017 ASCO Annual Meeting, we discuss homologous recombination deficiency in ovarian cancer and PARP inhibitors. (cancernetwork.com)
  • Indeed, at least in part, the abnormalities in homologous recombination deficiency have contributed to the very outstanding responses to platinum therapy and very striking new data with PARP (poly [ADP-ribose] polymerase) inhibitors. (cancernetwork.com)
  • In terms of the use of PARP inhibitors, the first two PARP inhibitors that were approved required testing for BRCA1/2 deficiency as a co-clinical test from the US Food and Drug Administration (FDA) for approval. (cancernetwork.com)
  • But, even the patients without either of those abnormalities had a modest improvement in progression-free survival with PARP inhibitors. (cancernetwork.com)
  • This is controversial, since the amount of benefit in those patients without either abnormalities in the pathway or in the homologous recombination defect assay are really quite modest, and whether this warrants the toxicity of the PARP inhibitors in these circumstances will require additional study. (cancernetwork.com)
  • He discovered the indenoisoquinolines as novel Top1 inhibitors, which are in clinical development, and the mitochondrial topoisomerase gene, TOP1mt. (cancer.gov)
  • To understand the determinants of response to topoisomerase inhibitors, he is studying the repair pathway centered on tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2) and poly(ADP-ribose)polymerases (PARP). (cancer.gov)
  • Three of his indenoisoquinoline TOP1 inhibitors are in Phase 1/2 clinical development (Thomas & Pommier, Clin Cancer Res 2019): LMP400 (Indotecan), LMP776 (Indimitecan) and LMP744. (cancer.gov)
  • 2020). Based on their promising clinical activity and their superior medicinal properties over the camptothecins, the indenoisoquinolines represent the first non-camptothecin TOP1 inhibitors for the treatment of cancers. (cancer.gov)
  • A total of 936 patients enrolled on the trial, 198 of whom received PARP inhibitors and 747 underwent active surveillance. (onclive.com)
  • After debulking surgery for initial diagnosis, 50% of patients receiving PARP inhibitors had no visible residual disease compared with 34% of those receiving active surveillance. (onclive.com)
  • Of those who were treated with PARP inhibitors, 33% received single-agent niraparib (Zejula), 34% received single-agent olaparib (Lynparza), 16% received single-agent rucaparib (Rubraca), and 16% received other regimens such as bevacizumab (Avastin) plus a PARP inhibitor or PARP inhibitor polytherapy. (onclive.com)
  • Real-world clinical outcomes with poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors as second-line maintenance therapy in patients with recurrent ovarian cancer in the United States. (onclive.com)
  • Our discussion provides a clinical pathway to guide clinicians on the selection of new upfront regimens for ovarian cancer incorporating bevacizumab and/or poly-adenosine diphosphate-ribose polymerase (PARP) inhibitors. (sutterhealth.org)
  • Background Poly-(ADP-Ribose)-Polymerase (PARP) inhibitors have become important stars of anti-neoplasic providers landscape, with latest but slim FDA's approvals for ovarian BRCA mutated malignancies and prostatic tumor. (cancerhugs.com)
  • Summary PARP inhibitors are guaranteeing radiosensitizers, but want more clinical analysis. (cancerhugs.com)
  • Therefore, several third-generation PARP inhibitors, some produced from the 3-Abdominal structure, have already been developed lately and examined in pre-clinical and medical studies. (cancerhugs.com)
  • Prior studies have shown that only a subset of patients will respond to PARP inhibitors. (mlo-online.com)
  • We believe using the HRD test may capture an enhanced number of responders to treatment with the exciting new class of PARP inhibitors. (mlo-online.com)
  • This article provides a concise and simplified overview of the development of PARP inhibitors in the laboratory and their clinical applications. (techscience.com)
  • Tyrosine Kinase Inhibitors (TKIs) have significantly improved the clinical outcome of BCR-ABL+ Chronic Phase-Chronic Myeloid Leukemia (CP-CML). (pakmedinet.com)
  • This study also indicates that a combination TKIs and Poly (ADP-ribose) polymerase (PARP) inhibitors like Olaparib (FDA approved anti-cancer drug for FA-pathway gene mutations) could improve the clinical outcome CML patients in accelerated and blast-crisis phases of the disease. (pakmedinet.com)
  • HRD also increases sensitivity to poly(ADP)-ribose polymerases (PARP), which led to the clinical development of PARP inhibitors. (ons.org)
  • In preclinical models of MM, synergy was observed in anti-tumor activity when poly (ADPribose) polymerase (PARP) inhibitors (olaparib, talazoparib) were used in combination with melphalan. (haematologica.org)
  • Germline aberrations in BRCA1 and BRCA2 genes are predictive biomarkers of response to poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib and platinum-based chemotherapy in PDAC, while mutations in mismatch repair genes identify patients suitable for immune checkpoint inhibitors. (escholarship.org)
  • Cancer patients whose tumours are driven by the loss of function of both copies of a predisposition gene may benefit from therapies targeting the biological alterations induced by the dysfunctional gene e.g. poly ADP ribose polymerase (PARP) inhibitors and other novel pathway agents in cancers with DNA repair deficiencies. (nih.gov)
  • Recent trials of therapies that target-defective DNA maintenance using poly (ADP-ribose) polymerase (PARP) inhibitors are showing promising results, yet invariably patients recur and succumb to disease. (gla.ac.uk)
  • PARP inhibitors have demonstrated marked efficacy in ovarian cancer patients with BRCA1/2 loss-of-function mutations. (bvsalud.org)
  • In this study, we established and validated a liquid chromatography-tandem mass spectrometry (LC-MS/MS) based method to simultaneously quantify the four frequently prescripted PARP inhibitors, namely niraparib, olaparibï¼ fluzoparib, and pamiparib, in ovarian cancer. (bvsalud.org)
  • Four PARP inhibitors were separated on a Hypersil GOLD™ aQ C18 Polar Endcapped LC column (50 × 2.1 mm, 1.9 µm) at 35 â and subjected to mass analysis using positive electro-spray ionization (ESI). (bvsalud.org)
  • The validated LC-MS/MS method allows the convient and efficient determination of four PARP inhibitors' exposure levels in ovarian cancer patients. (bvsalud.org)
  • Among them, poly (ADP-ribose) polymerase 1 (PARP1) plays a crucial role in DDR, and inhibitors targeting PARP1 have garnered extensive attention in anticancer research. (bvsalud.org)
  • Poly (ADP-ribose) polymerase inhibitors (PARPis) are approved for cancer therapy according to their synthetic lethal interactions, and clinical trials have been applied in non-small cell lung cancer. (bvsalud.org)
  • Tumour cells with these mutations demonstrate increased sensitivity to cisplatin and poly (ADP-ribose) polymerase (PARP) inhibitors. (ox.ac.uk)
  • DISCUSSION: This study aims to investigate whether 6MP might be an effective treatment for BRCA deficient tumours even after the development of resistance to PARP inhibitors or platinum drugs. (ox.ac.uk)
  • Described as a "milestone in the development of personalized treatment of recurrent ovarian carcinoma," PARP inhibitors function by impeding DNA repair. (ahdbonline.com)
  • PARP inhibitors and synthetic lethality generated a great deal of clinical enthusiasm at ASCO meetings dating back to 2009, with the reporting of the phase 2 study of iniparib in metastatic triple-negative breast cancer. (medscape.com)
  • Since then, clinical data with PARP inhibitors have been mixed. (medscape.com)
  • First, not all PARP inhibitors are created the same. (medscape.com)
  • Normal cells that don't replicate their DNA as often as cancer cells, and that lack any mutated BRCA1 or BRCA2 still have homologous repair operating, which allows them to survive the inhibition of PARP. (wikipedia.org)
  • Thus, reduction of inflammation by PARP-1 inhibition can mitigate these conditions. (wikipedia.org)
  • In the October 1 Journal of Clinical Investigation , Xueliang Du and colleagues at the Albert Einstein College of Medicine , show that inhibition of GAPDH activity by poly(ADP-ribose) polymerase (PARP) activates three major pathways of hyperglycemic damage in endothelial cells ( Journal of Clinical Investigation , 112:1049-1057, October 1, 2003). (the-scientist.com)
  • performed in vitro experiments on bovine aortic endothelial cells and observed that hyperglycemia-induced GAPDH inhibition was a consequence of poly(ADP-ribosyl)ation of GAPDH by PARP-activated by DNA strand breaks produced by mitochondrial superoxide overproduction. (the-scientist.com)
  • The negative prognosis associated with PARP1 and POLD2 expression along with the apparent melphalan-sensitizing effect of PARP inhibition may suggest this pathway as a potential biomarker in patients with MM in the setting of ASCT. (haematologica.org)
  • An important topic in breast cancer at ASCO this year was poly ADP ribose polymerase (PARP) inhibition. (medscape.com)
  • As poly adenosine diphosphate (ADP)-ribose polymerase 1 (PARP-1) is overexpressed in various cancer types, and is localized to the nucleus, PARP-1 can be safely targeted with Auger emitters to induce DNA damage in tumors. (osti.gov)
  • Olaparib is a type of drug called a PARP (poly [adenosine diphosphate-ribose] polymerase) inhibitor. (cancersa.org.au)
  • Approximately $2 million USD is allocated to this research grants program focused on investigating talazoparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in prostate cancer. (edu.au)
  • In a single-institution phase II study reported in the Journal of Clinical Oncology, Kim A. Reiss, MD, and colleagues found that maintenance treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib produced responses and was associated with good progression-free survival in. (ascopost.com)
  • Moreover, the identification of fork protection as a key mechanism of resistance to chemo- and poly (ADP-ribose) polymerase inhibitor therapy in ovarian cancer further increases the priority that should be accorded to the development of strategies targeting replicative stress. (bmj.com)
  • Myriad Genetics, Inc., has announced that Tesaro, Inc., will use Myriad's novel HRD (homologous recombination deficiency) test to identify tumor types that may respond to its investigational poly-ADP ribose polymerase (PARP) inhibitor, niraparib, currently in Phase 3 clinical development. (mlo-online.com)
  • The Company plans to initiate the Phase 2 portion of the TAMARACK Phase 2/3 study in patients with mCRPC who have had prior exposure to a taxane and at least one androgen receptor axis-targeted, or ARAT, agent (including abiraterone, enzalutamide or apalutimide), and a PARP (poly adenosine diphosphate-ribose polymerase) inhibitor, if appropriate. (macrogenics.com)
  • However, damaged DNA is repaired involving poly-(ADP-ribose) polymerase-1 (PARP-1) causing resistance to radiation therapy. (techscience.com)
  • NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-2 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® (enzalutamide) compared to placebo plus XTANDI in men with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene mutations. (pfizer.com)
  • In December 2014, the US Food and Drug Administration (FDA) granted accelerated approval to olaparib (Lynparza), an inhibitor of poly ADP-ribose polymerase (PARP), for the treatment of women with advanced ovarian cancer who received ≥3 chemotherapies and who have deleterious or suspected deleterious germline BRCA mutation, as detected by the FDA-approved companion diagnostic test BRACAnalysis CDx. (ahdbonline.com)
  • Unfortunately, this rarity has largely precluded prospective randomized clinical trials. (medscape.com)
  • The new drug applications (NDAs) submitted by the Pfizers and Mercks of the world are increasingly for out-of-house discoveries to which the world's biggest drugmakers biggest contribution is bankrolling, designing, and executing late-stage clinical trials. (pharmexec.com)
  • however, this clinical benefit may extend mPFS and categorize patients as "platinum-sensitive," allow them to be eligible for the re-treatment of platinum combinations, or become eligible for more clinical trials. (sutterhealth.org)
  • Carmen E. Guerra, MD, MSCE, of the University of Pennsylvania Abramson Cancer Center, discusses the ways in which community outreach, programs to help patients access cancer clinical trials, and insti. (ascopost.com)
  • Drawing on several lines of ongoing research, David A. Tuveson, MD, PhD, has created a theoretical framework to consider while developing clinical trials in pancreatic cancer. (ascopost.com)
  • Phase III clinical trials of Rova‑T for patients with small‑cell lung cancer and a phase III clinical trial of nirogacestat for patients with desmoid tumors are ongoing. (spandidos-publications.com)
  • As part of our mission to eliminate cancer, MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers. (mdanderson.org)
  • The efficacy of rucaparib was established in Study 10 and in the ARIEL2 study, 2 open-label, single-arm, multicenter clinical trials of 106 patients with advanced BRCA mutation-positive ovarian cancer who received at least 2 previous chemotherapy regimens. (ahdbonline.com)
  • Results from a clinical trial of olaparib in 137 patients with BRCA mutation-positive ovarian cancer who had received ≥3 chemotherapy regimens demonstrated an investigator-assessed overall response rate of 34% and a median duration of response of 7.9 months. (ahdbonline.com)
  • These data support the utility of PARP-1 targeted radiopharmaceutical therapy as a theranostic option for PARP-1 overexpressing ovarian cancers. (osti.gov)
  • Here we describe the premise for targeting of replicative stress in gynecological cancers and discuss the clinical advancement of this strategy. (bmj.com)
  • Patients with recurrent ovarian cancer who received PARP inhibitor maintenance treatment in the second-line setting experienced a longer time to next treatment and overall survival compared with those who were just under active surveillance. (onclive.com)
  • Patients with recurrent ovarian cancer who received PARP inhibitor maintenance treatment in the second-line setting experienced a longer time to next treatment (TTNT) and overall survival (OS) compared with those who were just under active surveillance, according to findings from a real-world analysis presented during the 2022 SGO Annual Meeting. (onclive.com)
  • Rucaparib is an inhibitor of PARP, an enzyme that is involved in repairing damaged DNA. (ahdbonline.com)
  • Several forms of cancer are more dependent on PARP than regular cells, making PARP (PARP1, PARP2 etc) an attractive target for cancer therapy. (wikipedia.org)
  • Across 450 clinical samples and six disease stages, expression levels of genes in the BER pathway were found to be highly upregulated during the development of MM. In a separate cohort of 559 patients with MM treated with ASCT, expression of BER pathway members MPG and PARP3 was positively associated with overall survival (OS) while expression of PARP1, POLD1, and POLD2 was negatively associated with OS. (haematologica.org)
  • Finally, we showed tumors can be imaged by single-photon computed tomography (SPECT) with PARP theranostic, [ 123 I]KX1, in a human ovarian cancer xenograft mouse model. (osti.gov)
  • GETNE1509) reported in the Journal of Clinical Oncology, Jaume Capdevila, MD, and colleagues found that lenvatinib produced durable responses in patients with previously treated advanced grade 1 or 2 gastroenteropancreatic neuroendocrine tumors. (ascopost.com)
  • Selinexor, a small molecule that inhibits nuclear export protein XPO1, has demonstrated efficacy in solid tumors and hematologic malignancies with the evidence of clinical activity in sarcoma as a single agent. (aacrjournals.org)
  • There are few, if any, more difficult clinical challenges than pancreatic cancer, a disease that continues to confound the oncology community's quest for cure. (ascopost.com)
  • Methods: Here we present a case of a 63-year-old female patient with a germ line pathogenic BRCA2 mutation (6714 deletion) who developed pancreatic cancer and had an exceptional response to platinum and PARP inhibitor therapy. (gla.ac.uk)
  • Sequence analysis of these genes is being used to identify BRCA1/2 mutation carriers, though these efforts are hampered by the high frequency of variants of unknown clinical significance (VUSs). (jci.org)
  • Genetic testing for deleterious mutations in breast cancer 1, early onset gene ( BRCA1 ) and BRCA2 can provide key information to guide clinical decision making. (jci.org)
  • Through this funding mechanism, PCF and Pfizer will support approximately three (3) innovative clinical investigations or clinical trial correlative research studies surrounding the use of talazoparib in prostate cancer. (edu.au)
  • however, resistance invariably arises in these patients and is a major clinical problem. (jci.org)
  • Mechanisms of resistance to platinum-based and PARP inhibitor therapy in other cancer types include secondary mutations, which restore the integrity of DNA repair through an increasing number of different mechanisms. (gla.ac.uk)
  • Through nextgeneration sequencing and clinical follow-up, we correlated tumour response and resistance to the BRCA2 mutational status in the tumour. (gla.ac.uk)
  • Conclusions: To our knowledge, this is the first report of a BRCA2 reversion mutation that conferred resistance to PARP inhibitorbased therapy in a pancreatic ductal adenocarcinoma patient. (gla.ac.uk)
  • 6MP was identified in a screen for novel drugs and found to selectively kill BRCA-defective cells in a xenograft model as effectively as the PARP inhibitor AGO14699, even after these cells had acquired resistance to a PARP inhibitor or cisplatin. (ox.ac.uk)
  • As part of our coverage of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2-6 in Chicago, we are speaking with Gordon Mills, MD, PhD, chair of the department of systems biology and professor of medicine and immunology at the University of Texas MD Anderson Cancer Center in Houston, about ways to incorporate homologous recombination markers into clinical practice for ovarian cancer. (cancernetwork.com)
  • Yet unresolved challenges lie in balancing the toxicity profile of these drugs in order to achieve a suitable therapeutic index while maintaining clinical efficacy, and selective biomarkers are urgently required. (bmj.com)
  • It also discusses the need for optimal approaches to better select patients for PARP inhibitor therapy, novel therapeutic opportunities under clinical investigation, and preclinical models for cancer susceptibility and drug discovery. (escholarship.org)
  • 4 Maintenance therapy (or postremission therapy) with pazopanib (Votrient) or bevacizumab (Avastin) can be considered in some clinical circumstances. (ahdbonline.com)
  • This will potentially be of benefit in opening up appropriate clinical trial opportunities for this subset of patients in the future. (cancernetwork.com)
  • Similar findings were reported among patients with a BRCA mutation (21% vs 8%) and those with an ECOG performance status of 0 to 1 (79% vs 69%) who received PARP maintenance and active surveillance, respectively. (onclive.com)
  • 1 Although ASCT provides significant benefits to some patients with MM, it is not curative and is associated with significant heterogeneity in clinical benefit. (haematologica.org)
  • 3 Patients achieving deeper remission receive the greatest duration of clinical benefit following ASCT. (haematologica.org)
  • Despite a weak effect on the cause of the disease itself in MPNs, ruxolitinib improves the clinical state of patients and increases survival in myelofibrosis. (pvreporter.com)
  • A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol. (ox.ac.uk)
  • Understanding the clinical course of genotype-negative MEN1 patients can inform management strategies. (cdc.gov)
  • PARPi suppress activity of PARP catalytic website explaining artificial lethality in HR faulty cells. (cancerhugs.com)
  • In stage II-III clinical tests learning PARPi monotherapy, toxicity continues to be manageable and is composed more often than not of anemia, thrombocytopenia, neutropenia, asthenia and nauseas hardly ever upper than quality II [23C26]. (cancerhugs.com)
  • Inhibiting PARP-1 is lethal in a wide range of cancer cells that lack the homologous recombination repair (HR) pathway. (techscience.com)
  • Thus, PARP-1 represents an important target in multiple cancer types, including prostate cancer. (techscience.com)
  • Exclusion criteria included those with an incomplete medical history, borderline histology, or treatment with a non-PARP inhibitor therapy within 120 days of the index date, as well as those who received PARP inhibitor monotherapy as a first- or second-line treatment. (onclive.com)
  • Preliminary results from the dose escalation phase of this study were presented at the 2020 American Society for Clinical Oncology (ASCO) Scientific Program. (macrogenics.com)
  • Distinct Clinical Characteristics in Young-Onset Pancreatic Neuroendocrine Tumor. (cdc.gov)
  • There have been significant ups and downs in the PARP story before ASCO 2017. (medscape.com)
  • We have evaluated three clinical decision points with biomarker guidance that must be made in the upfront treatment of ovarian cancer. (sutterhealth.org)
  • In the population with BRCA mutations, investigators reported a median OS of of 47.1 months (95% CI, 26.4-47.1) vs 43.8 months (95% CI, 22.3-not reached) in the PARP inhibitor and active surveillance groups, respectively. (onclive.com)
  • Inclusion criteria included those receiving PARP inhibitor therapy within 120 days after index or would be relegated to the active surveillance group if not. (onclive.com)
  • Results: Initially, the patient had an exceptional response to platinum and PARP inhibitor therapy, most likely due to the BRCA2 mutation. (gla.ac.uk)
  • However, the primary lesion recurred while on PARP inhibitor therapy and contained a secondary mutation in BRCA2, which mostly likely restored BRCA2 function in PARP inhibitor-resistant tumour cells. (gla.ac.uk)
  • Excessive PARP-1 activity may exacerbate the pathogenesis of stroke, myocardial infarction, neurodegeneration, and a number of other disease conditions due to excessive inflammation. (wikipedia.org)
  • Further research into the clinical implications of variants in moderate penetrance genes, particularly in unaffected carriers, is needed for appropriate counselling and risk management with data-driven plans for surveillance and/or risk reduction. (nih.gov)
  • The goal of this activity is for learners to be better able to highlight the latest clinical data in ovarian cancer presented in Paris 2022. (medscape.org)
  • Selinexor, an inhibitor of XPO1, has shown preclinical and clinical activity in sarcoma. (aacrjournals.org)
  • This was critical for the clinical development of Yondelis. (cancer.gov)
  • The median follow-up was 14.2 months for the PARP inhibitor group compared with 6.7 months in the active surveillance group. (onclive.com)
  • Those with a BRCA mutation had a median time to next treatment of 13.2 months (95% CI, 10.3-22.1) vs 7.1 months (95% CI, 5.2-9.9) in the PARP inhibitor and active surveillance groups, respectively. (onclive.com)
  • As Chief, Dr. Pommier oversees the Branch's clinical/translational research program, which emphasizes new approaches to cancer treatments targeting DNA, epigenetic and chromatin, and connected biomarkers. (cancer.gov)
  • Commenting on this study on clinical genomic profiling for colorectal cancer, Lisa Newman, MD, MPH, FACS, FASCO, Chief of the Section of Breast Surgery and leader of the Multidisciplinary Breast Onco. (ascopost.com)
  • Because of these results, a human clinical trial with selinexor in combination with a proteasome inhibitor is planned for the treatment of sarcoma. (aacrjournals.org)
  • 3] The National Cancer Institute (NCI) recommends that high-risk women seek advice from their physicians and consider having annual ultrasonographic examinations and annual CA125 testing, as well as consider oophorectomy or participation in a clinical trial. (medscape.com)
  • Instead, if a clinical suggestion of ovarian cancer is present, the patient should undergo laparoscopic evaluation or laparotomy, based on the presentation, for diagnosis and staging. (medscape.com)
  • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2019 3 25 (6): 580-588. (cdc.gov)
  • This review focuses on clinical developments and management of newly diagnosed glioblastoma, and includes a discussion about the incorporation of molecular features into the classification of this disease. (cancernetwork.com)
  • Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland. (nih.gov)